UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral Therapy

Clinical pharmacology and therapeutics, 2019-10, Vol.106 (4), p.726-733

2019

Volltextzugriff (PDF)

Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives

The Lancet infectious diseases, 2018-03, Vol.18 (3), p.e64-e75

2018

Volltextzugriff (PDF)

Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent

AIDS (London), 2011-06, Vol.25 (10), p.1271-1280

2011

Volltextzugriff (PDF)

Pharmacogenetics of tenofovir clearance among Southern Africans living with HIV

Pharmacogenetics and genomics, 2023-06, Vol.33 (4), p.79-87

2023

Volltextzugriff (PDF)

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment

AIDS (London), 2009-06, Vol.23 (9), p.1109-1118

2009

Volltextzugriff (PDF)

Tissue specificity-aware TWAS (TSA-TWAS) framework identifies novel associations with metabolic, immunologic, and virologic traits in HIV-positive adults

PLoS genetics, 2021-04, Vol.17 (4), p.e1009464

2021

Volltextzugriff (PDF)

Maternal education and child nutritional status in Bolivia: finding the links

Social science & medicine (1982), 2005, Vol.60 (2), p.395-407

2005

Volltextzugriff (PDF)

Effect of CYP2B6, ABCB1, and CYP3A5 Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study

The Journal of infectious diseases, 2010-09, Vol.202 (5), p.717-722

2010

Volltextzugriff (PDF)

HIV infection of naturally occurring and genetically reprogrammed human regulatory T-cells

PLoS biology, 2004-07, Vol.2 (7), p.E198

2004

Volltextzugriff (PDF)

Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles

Scientific reports, 2017-08, Vol.7 (1), p.8653-12, Article 8653

2017

Volltextzugriff (PDF)

Associations between HLA-DRB10102, HLA-B5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa

Journal of acquired immune deficiency syndromes (1999), 2013-02, Vol.62 (2), p.e55-e57

2013

Volltextzugriff (PDF)

Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals

Journal of antimicrobial chemotherapy, 2018-09, Vol.73 (9), p.2460-2467

2018

Volltextzugriff (PDF)

HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins

PloS one, 2009-08, Vol.4 (8), p.e6687-e6687

2009

Volltextzugriff (PDF)

The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients

Pharmacogenetics and genomics, 2012, Vol.22 (1), p.32-42

2012

Volltextzugriff (PDF)

Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype

AIDS (London), 2013-07, Vol.27 (12), p.1933-1940

2013

Volltextzugriff (PDF)

Pharmacogenetics of Long-Term Responses to Antiretroviral Regimens Containing Efavirenz and/or Nelfinavir: An Adult AIDS Clinical Trials Group Study

The Journal of infectious diseases, 2005-12, Vol.192 (11), p.1931-1942

2005

Volltextzugriff (PDF)

Associations between CYP2B6 Polymorphisms and Pharmacokinetics after a Single Dose of Nevirapine or Efavirenz in African Americans

The Journal of infectious diseases, 2009-03, Vol.199 (6), p.872-880

2009

Volltextzugriff (PDF)

Pharmacokinetics of Phase I Nevirapine Metabolites following a Single Dose and at Steady State

Antimicrobial Agents and Chemotherapy, 2013-05, Vol.57 (5), p.2154-2160

2013

Volltextzugriff (PDF)

Pharmacokinetics of Acyclovir and Its Metabolites in Cerebrospinal Fluid and Systemic Circulation after Administration of High-Dose Valacyclovir in Subjects with Normal and Impaired Renal Function

Antimicrobial Agents and Chemotherapy, 2010-03, Vol.54 (3), p.1146-1151

2010

Volltextzugriff (PDF)

Implications of Efavirenz Pharmacogenetics When Switching From Efavirenz- to Dolutegravir-containing Antiretroviral Regimens

Clinical infectious diseases, 2021-05, Vol.72 (10), p.1820-1822

2021

Volltextzugriff (PDF)

Genetic and non-genetic determinants of raltegravir penetration into cerebrospinal fluid: a single arm pharmacokinetic study

PloS one, 2013-12, Vol.8 (12), p.e82672

2013

Volltextzugriff (PDF)

Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid

Southern African journal of HIV medicine, 2021, Vol.22 (1), p.1206-e24

2021

Volltextzugriff (PDF)

The Middle East and the United States: History, Politics, and Ideologies

Sixth edition., 2018

Volltextzugriff (PDF)

Immunogenetics of CD4 Lymphocyte Count Recovery during Antiretroviral Therapy: An AIDS Clinical Trials Group Study

The Journal of infectious diseases, 2006-10, Vol.194 (8), p.1098-1107

2006

Volltextzugriff (PDF)

Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral dose

British journal of clinical pharmacology, 2013-04, Vol.75 (4), p.997-1006

2013

Volltextzugriff (PDF)

1 – 25 von 918

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(798)
Mit Volltextzugriff
(722)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral Therapy

Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives

Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent

Pharmacogenetics of tenofovir clearance among Southern Africans living with HIV

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment

Tissue specificity-aware TWAS (TSA-TWAS) framework identifies novel associations with metabolic, immunologic, and virologic traits in HIV-positive adults

Maternal education and child nutritional status in Bolivia: finding the links

Effect of CYP2B6, ABCB1, and CYP3A5 Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study

HIV infection of naturally occurring and genetically reprogrammed human regulatory T-cells

Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles

Associations between HLA-DRB10102, HLA-B5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa

Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals

HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins

The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients

Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype

Pharmacogenetics of Long-Term Responses to Antiretroviral Regimens Containing Efavirenz and/or Nelfinavir: An Adult AIDS Clinical Trials Group Study

Associations between CYP2B6 Polymorphisms and Pharmacokinetics after a Single Dose of Nevirapine or Efavirenz in African Americans

Pharmacokinetics of Phase I Nevirapine Metabolites following a Single Dose and at Steady State

Pharmacokinetics of Acyclovir and Its Metabolites in Cerebrospinal Fluid and Systemic Circulation after Administration of High-Dose Valacyclovir in Subjects with Normal and Impaired Renal Function

Implications of Efavirenz Pharmacogenetics When Switching From Efavirenz- to Dolutegravir-containing Antiretroviral Regimens

Genetic and non-genetic determinants of raltegravir penetration into cerebrospinal fluid: a single arm pharmacokinetic study

Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid

The Middle East and the United States: History, Politics, and Ideologies

Immunogenetics of CD4 Lymphocyte Count Recovery during Antiretroviral Therapy: An AIDS Clinical Trials Group Study

Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral dose

Suchergebnisse filtern